---
title: "Vaxart Shareholders Reject Executive Pay at Annual Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293079968.md"
description: "Vaxart shareholders rejected the non-binding advisory proposal for executive compensation at its July 16, 2026 annual meeting, signaling dissatisfaction with pay practices. While investors approved director elections and auditor ratification, the rejection pressures the board to reassess compensation policies. The company remains a clinical-stage biotech focused on oral vaccines."
datetime: "2026-07-17T21:30:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293079968.md)
  - [en](https://longbridge.com/en/news/293079968.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293079968.md)
generator: "portal-rs"
---

# Vaxart Shareholders Reject Executive Pay at Annual Meeting

Vaxart ( (VXRT) ) just unveiled an announcement.

On July 16, 2026, Vaxart held its annual meeting of stockholders in a virtual-only format, with a quorum representing about 45.7% of outstanding shares. Shareholders approved the election of six directors to serve until the 2027 meeting and ratified WithumSmith+Brown, PC as the company’s independent registered public accounting firm for the 2026 fiscal year.

However, investors rejected, on a non-binding advisory basis, the proposed compensation of Vaxart’s named executive officers, signaling shareholder dissatisfaction with current pay practices. The mixed voting outcome maintains governance continuity and auditor oversight while adding pressure on the board to reassess executive compensation policies and respond to investor concerns. 

**Spark’s Take on VXRT Stock**

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

VXRT scores in the mid-range primarily due to improved financial performance (turn to profitability and positive free cash flow with low leverage) but with meaningful durability risk given historically volatile, loss-making results and prior cash burn. Technical indicators are mixed and slightly extended near-term, while valuation is supported by a very low P/E. Corporate events are a net positive, led by encouraging safety readouts and governance stabilization alongside continued federal trial funding.

To see Spark’s full report on VXRT stock,  
 click here. 

**More about Vaxart**

Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines delivered as shelf-stable pills using its proprietary platform. Its pipeline includes pill vaccines targeting coronavirus, norovirus and influenza, as well as a therapeutic HPV vaccine, with broad patent filings covering its oral adenovirus and TLR3-based vaccination technology.

The company aims to offer oral versions of existing injectable vaccines and novel recombinant vaccines for new indications, emphasizing ease of storage and distribution without refrigeration and eliminating needle-stick risk. This positions Vaxart in the emerging segment of innovative vaccine delivery technologies seeking differentiated product profiles and potential public-health advantages. 

**Average Trading Volume:** 394,205

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $124.6M

### Related Stocks

- [VXRT.US](https://longbridge.com/en/quote/VXRT.US.md)

## Related News & Research

- [U-Haul Holding held annual shareholder meeting, voted on director slate](https://longbridge.com/en/news/296823748.md)
- [ING (ENXTAM:INGA) Stock Could Be 50% Undervalued Despite Stake Sale](https://longbridge.com/en/news/296514948.md)
- [Apollo Commercial Real Estate Finance announces special shareholder meeting](https://longbridge.com/en/news/296831063.md)
- [Patient Capital Management LLC Buys Shares of 204,022 Dave & Buster's Entertainment, Inc. $PLAY](https://longbridge.com/en/news/296774300.md)
- [GEE Group announces virtual annual shareholder meeting](https://longbridge.com/en/news/296654866.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**